Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Javier Gonzalez

Cardiovascular Disease The Villages, FL Medical Doctor

NPI 1689658809 CMS profile 166591

910 Old Camp Rd, Bldg 210, The Villages, FL 32162

Open in the dashboard

General payments

$17,757

519 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Javier Gonzalez of The Villages, FL is reported in the CMS Open Payments database as having received $17,757 across 519 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,805 96
2024 General $1,632 75
2023 General $4,308 83
2022 General $2,052 72
2021 General $1,309 53
2020 General $1,678 66
2019 General $1,973 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javier Gonzalez
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Javier Gonzalez were reported at $4,805. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Javier Gonzalez Cardiovascular Disease median Middle half National median
2019 $1,973 $450 $127–$1,392 $163
2020 $1,678 $242 $77–$751 $114
2021 $1,309 $335 $101–$1,037 $132
2022 $2,052 $395 $121–$1,211 $149
2023 $4,308 $443 $136–$1,283 $160
2024 $1,632 $450 $136–$1,323 $164
2025 $4,805 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,655 28 payments
  2. Boston Scientific Corporation $2,541 27 payments
  3. CVRx, Inc. $1,595 11 payments
  4. Amgen Inc. $1,022 40 payments
  5. Pfizer Inc. $932 44 payments
  6. AstraZeneca Pharmaceuticals LP $746 29 payments
  7. Janssen Pharmaceuticals, Inc $717 25 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $707 39 payments
  9. Novartis Pharmaceuticals Corporation $700 44 payments
  10. E.R. Squibb & Sons, L.L.C. $595 32 payments
  11. Other $5,547 200 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,162 497 payments
  2. Travel and Lodging $3,184 11 payments
  3. Education $373 10 payments
  4. Debt forgiveness $38 1 payment
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System $1,715 6 payments
  2. TRICLIP $1,657 7 payments
  3. Barostim Neo System $1,595 11 payments
  4. Repatha $863 31 payments
  5. XARELTO $717 25 payments
  6. LifeVest $707 39 payments
  7. VYNDAQEL $632 27 payments
  8. VERQUVO $561 26 payments
  9. ELIQUIS $416 23 payments
  10. LEQVIO $389 24 payments
  11. Other $9,336 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

6,375

Median for Cardiology: 2,533

Drug cost

$1,552,419

Median for Cardiology: $485,213

Branded share of claims

32%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 615 $723,889
Entresto Sacubitril/Valsartan Brand 167 $210,453
Xarelto Rivaroxaban Brand 83 $120,431
Repatha Sureclick Evolocumab Brand 115 $116,615
Multaq Dronedarone Hcl Brand 51 $99,261
Farxiga Dapagliflozin Propanediol Brand 66 $60,199
Jardiance Empagliflozin Brand 34 $43,476
Repatha Syringe Evolocumab Brand 31 $34,756
Ranolazine Er Ranolazine Brand 196 $18,826
Praluent Pen Alirocumab Brand 22 $15,288

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$1,261,937

Of which drugs: $6,929

Medicare patients

1,614

Average age 78

Services billed

11,476

762 women, 852 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Arthritis 56%
Chronic kidney disease 45%
Atrial fibrillation 43%
Diabetes 40%
Heart failure 35%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 331 1,332 $6,859

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $251
$251 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $183
$183 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $107
$107 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $77
$77 — —
ELIQUIS
  • PFIZER INC. $36
  • E.R. Squibb & Sons, L.L.C. $33
$69 615 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

519 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record